Northwest Biotherapeutics reported $-108.65M in Operating Expenses for its fiscal quarter ending in September of 2025.





Operating Expenses Change Date
Agenus USD -221.22M 241.03M Mar/2026
AstraZeneca USD 8.18B 4.35B Mar/2026
Bristol-Myers Squibb USD 20.07B 11.77B Mar/2026
Celldex Therapeutics USD 456.23M 368.95M Mar/2026
Eisai JPY 215.74B 15.84B Mar/2026
Infinity Pharmaceuticals USD 10.7M 1.54M Jun/2023
Merck USD 18.17B 8.01B Mar/2026
Northwest Biotherapeutics USD -108.65M 8.26M Sep/2025
Pfizer USD 90.1B 77.19B Mar/2026
Plus Therapeutics USD 7.11M 1.23M Dec/2025
Roche Holding CHF 21.01B 10.84B Dec/2025